DESTINY-Breast03 Phase 3 Study Results
Time to First Occurrence of Nausea and Vomiting
10
Daiichi-Sankyo
DESTINY-Breast03
Nausea
+ Censor
1.0
Cumulative Probability
0.9
P<0.0001
0.8
0.7
0.6
0.5
0.4
T-DXd
T-DM1
0.3
0.2
Cumulative Probability
+
1.0¬
Censor
T-DXd
Vomiting
0.9-
T-DM1
P<0.0001
0.8-
0.7-
0.6-
www
0.5
0.4-
0.3-
0.2-
படட
0.1
0.1
0.0
0.0
0
90
180
270
360
450
540
630
720
810
900
990
1080
0
90
180
270
360
450
540
630
720
810
900
990
1080
Days
Days
T-DXd 257
T-DM1 261
71
150
59
100
46
37
27
74
50
39
22
20
9
6
29
15
4
42
1
0
0
T-DXd 257
T-DM1 261
153
133
115
95
202
141
95
66
24
79
55
47
53
29
14
8
3
1
0
34
19
7
3
0
Risk of first event of nausea and vomiting was higher with T-DXd in earlier cycles
T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event.
Time to first occurrence of the TEAE was defined as the date of the first occurrence of the TEAE minus the date of first study drug plus 1. Patients that did not experience the TEAE were censored at min (treatment end date + 47 days, new treatment start date,
death date, date last known alive) minus first study drug date plus 1. P value was from the unstratified log rank test and was for descriptive purposes only.
ASCO 2022 #1000 Oral
30View entire presentation